Misty Shields, Assistant Professor at Indiana University School of Medicine, Indiana University Health, shared a post on LinkedIn:
“Relapse in SCLC is unfortunately too common.
Historically, chemotherapy-free intervals (CTFI) following last platinum exposure to relapse have been utilized to help prognosticate outcomes for patients with ES-SCLC.
Turns out, not all relapse in SCLC is the same…
In this publication, led by Dr. Paresh Kumar, we demonstrate how radiographic patterns of progression impact outcomes for patients with ES-SCLC receiving chemoIO.
Patients w/ oligoprogression (OP) after chemoIO:
- Improved overall survival (17.5 vs 8.6 mo)
- Survival post-progression (11.1 vs 2.3 mo)
- More likely to be female (75% vs 25%)
Patients w/ multi-focal POD (non-OP) after chemoIO:
- More likely to be hospitalized (66.7% vs 29.8%)
- Receive fewer subsequent therapies (58% vs 89%)
- Transition to hospice within 3 mo (50% vs 6.4%)
Importantly, CTFI failed to predict post-progression OS in our cohort (HR 1.62).
Translational biomarker analysis from liquid biopsies highlighted that patients with non-OP are enriched in hypermethylation of CpGs in HOXA5, a key tumor suppressor and transcription factor that typically binds to the promoter of p53 to induce apoptosis.
Call to action: Progression patterns in SCLC matter. Patients with non-OP should be prioritized for trials, as they are at higher risk for fewer treatment options, hospitalization, and mortality.”
Title: Prognostic Significance and Biomarker Identification by Progression Patterns in Patients With Small Cell Lung Cancer After Immune Checkpoint Inhibitors
Authors: Paresh Kumar, James Slaven, Tianhao Zhou, Mya Tran, Misty Shields
Read the Full Article.
You can also read:
Can a Routine CT Scan Predict PD-L1 Expression in Metastatic NSCLC?
